![Full article: Risk of dosing errors in ART treatment: user experience of single- vs multi-use follitropin alfa pens Full article: Risk of dosing errors in ART treatment: user experience of single- vs multi-use follitropin alfa pens](https://www.tandfonline.com/cms/asset/66c1a9af-1768-4c2e-bc21-df0c061535a4/iedd_a_1863944_f0002_oc.jpg)
Full article: Risk of dosing errors in ART treatment: user experience of single- vs multi-use follitropin alfa pens
![These highlights do not include all the information needed to use Gonal-f® RFF Redi-ject® safely and effectively. See full prescribing information for Gonal-f® RFF Redi-ject® Gonal-f® RFF* Redi-ject® (follitropin alfa injection) for These highlights do not include all the information needed to use Gonal-f® RFF Redi-ject® safely and effectively. See full prescribing information for Gonal-f® RFF Redi-ject® Gonal-f® RFF* Redi-ject® (follitropin alfa injection) for](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=gonal-f-29.jpg&id=618885)
These highlights do not include all the information needed to use Gonal-f® RFF Redi-ject® safely and effectively. See full prescribing information for Gonal-f® RFF Redi-ject® Gonal-f® RFF* Redi-ject® (follitropin alfa injection) for
![Amazon.com: LABO Nutrition VesseCLEAR EX: Nattokinase NSK-SD+Elastin F for Clean & Flexible Blood Vessel. Japan's Most Clinically Studied, Functional Dose : Health & Household Amazon.com: LABO Nutrition VesseCLEAR EX: Nattokinase NSK-SD+Elastin F for Clean & Flexible Blood Vessel. Japan's Most Clinically Studied, Functional Dose : Health & Household](https://m.media-amazon.com/images/I/712q2brhjlL._AC_UF1000,1000_QL80_.jpg)
Amazon.com: LABO Nutrition VesseCLEAR EX: Nattokinase NSK-SD+Elastin F for Clean & Flexible Blood Vessel. Japan's Most Clinically Studied, Functional Dose : Health & Household
![These highlights do not include all the information needed to use Gonal-f® RFF Redi-ject® safely and effectively. See full prescribing information for Gonal-f® RFF Redi-ject® Gonal-f® RFF* Redi-ject® (follitropin alfa injection) for These highlights do not include all the information needed to use Gonal-f® RFF Redi-ject® safely and effectively. See full prescribing information for Gonal-f® RFF Redi-ject® Gonal-f® RFF* Redi-ject® (follitropin alfa injection) for](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=gonal-f-05.jpg&id=618885)
These highlights do not include all the information needed to use Gonal-f® RFF Redi-ject® safely and effectively. See full prescribing information for Gonal-f® RFF Redi-ject® Gonal-f® RFF* Redi-ject® (follitropin alfa injection) for
![Frontiers | Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization Frontiers | Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization](https://www.frontiersin.org/files/Articles/1089862/fphar-14-1089862-HTML-r1/image_m/fphar-14-1089862-g001.jpg)
Frontiers | Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization
![Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial - The Lancet Respiratory Medicine Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/asset/0ed07044-02d7-4c0e-95a7-b9a3d949e5df/gr1.jpg)
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial - The Lancet Respiratory Medicine
![Frontiers | Determining Out-of-Field Doses and Second Cancer Risk From Proton Therapy in Young Patients—An Overview Frontiers | Determining Out-of-Field Doses and Second Cancer Risk From Proton Therapy in Young Patients—An Overview](https://www.frontiersin.org/files/MyHome%20Article%20Library/892078/892078_Thumb_400.jpg)
Frontiers | Determining Out-of-Field Doses and Second Cancer Risk From Proton Therapy in Young Patients—An Overview
![FYARRO® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) dosing schedule FYARRO® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) dosing schedule](https://d34ifdh5mu6kme.cloudfront.net/fyarro-hcp-website/images/Fyarro_Vial_RGB.png)